fbpx
Donate Toggle Menu

Dr. Yuexin Xu received a 2024 Kidney Cancer Association Trailblazer Award for research on “Characterization of tumor endothelial STAB1-mediated Treg recruitment into renal cell carcinoma.” Dr. Xu is a researcher based at Fred Hutchinson Cancer Research Center in Seattle, Washington. This is the second research grant Dr. Xu has received from the KCA. We spoke with her about her research and the impact it could have on people with kidney cancer.

Tell us about your research project and how you developed the idea.

Dr. Yuexin Xu received a KCA research grant in 2021.

Our project focuses on a unique approach to kidney cancer treatment by targeting the tumor’s immune environment. In certain cancers, specific cells called T regulatory cells (Tregs) are recruited into tumors, creating an environment that weakens the immune system’s ability to fight cancer. We found that a molecule called STAB1 plays a key role in attracting these Tregs into kidney tumors. By understanding how STAB1 functions, we aim to develop therapies that block this process, potentially improving immune responses and outcomes for kidney cancer patients.

This idea developed from observing that despite advanced treatments, some tumors still resist the immune system’s attacks. By exploring why this resistance happens, we identified STAB1 as a significant factor, which led us to focus on methods to counteract its effects.

What about your research do you think should be most exciting to patients/families?

  Our research has the potential to enhance immunotherapy, which uses the patient’s own immune system to combat cancer. By targeting the mechanisms that allow tumors to shield themselves from immune cells, we’re working to empower the body’s natural defenses to fight more effectively. This means patients may have a stronger, more direct tool against cancer that aligns with their body’s natural responses. The idea that a patient’s immune system can be “reawakened” to recognize and attack cancer cells is not only scientifically powerful but also offers a hopeful path forward, especially for those whose cancers haven’t responded to other treatments.

What motivates you? 

 My motivation is fueled by the invaluable guidance I’ve received from my mentors. During my PhD, my mentor, Dr. Minsoo Kim, instilled in me the importance of pursuing science with passion and honesty. My current PI, Dr. Edus Warren, has continued to support that foundation while encouraging innovation and the freedom to explore new ideas. Together, their mentorship has shown me that impactful science is built on integrity and creativity. This supportive environment drives me to push boundaries, knowing that each step in research has the potential to make a real difference for patients and for the scientific community.

What else do you want others to know about you or your research?

I want others to know that cancer research is as much about resilience as it is about innovation. Tackling cancer means pushing boundaries, questioning norms, and finding solutions that may have previously seemed impossible. Our team is dedicated not only to understanding cancer better but also to turning these insights into real, effective treatments. It’s a journey that requires collaboration, dedication, and a continuous drive to make a difference.

Recent Blog Posts

image for blog post AUC3 Highlights

AUC3 Highlights

January 30, 2025

Attendees at the inaugural Advanced Urologic Cancer Consensus Conference (AUC3) met in Miami, Florida on January 23-24 to agree on…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *